Premium
Interferon‐γ in vivo reverses the increased platelet levels of platelet‐derived growth factor and transforming growth factor‐β in patients with myelofibrosis with myeloid metaplasia
Author(s) -
Martyré MarieClaire,
Magdelenat Henri,
Calvo Fabien
Publication year - 1991
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1991.tb08596.x
Subject(s) - platelet derived growth factor receptor , myelofibrosis , growth factor , platelet , medicine , transforming growth factor , platelet derived growth factor , endocrinology , in vivo , interferon , myeloid , immunology , biology , bone marrow , receptor , microbiology and biotechnology
Summary We previously reported high platelet‐derived growth factor (PDGF) and transforming growth factorβ (TGF‐β) levels in platelets from patients with myelofibrosis with myeloid metaplasia. We report here the effects of in vivo administration of recombinant human interferon‐γ on these growth factor levels. Of six patients who entered this study in our institution, four completed the 6‐month therapy trial with interferon‐γ PDGF and TGF‐β levels in platelets were evaluated before and after treatment. PDGF levels were determined using a radioimmunoassay and TGF‐β activity was measured using an inhibition growth assay on CC164 cells. In these four patients, IFN‐γ therapy led to a reduction of the increased PDGF and TGF‐β levels in platelets towards the normal range. PDGF and TGF‐β values decreased by 25–45% and 32–46%, respectively. An acute deterioration was observed in one patient 5 months after the end of IFN‐γ therapy. In this patient, the deterioration of his clinical state correlated with an increase in intraplatelet PDGF and TGF‐β levels.